Whalesbook
Ahmedabad-based Corona Remedies is posting strong growth by acquiring older, neglected pharmaceutical brands from giants like Dr. Reddy's and Sanofi. By focusing on established names like Wokadine and Myoril, the company achieved a 17.3% revenue jump to ₹1,403 crore in FY26. Investors are noting how this strategy avoids the high costs of new drug development while leveraging existing doctor familiarity.
What Happened
Corona Remedies, based in Ahmedabad, is expanding its business by acquiring established pharmaceutical brands that large companies no longer prioritize. This strategy focuses on buying "tail brands," which are established products with a history of use but which have lost attention within the portfolios of larger pharmaceutical firms.
In March 2026, the company acquired Wokadine, a povidone-iodine brand, from Dr. Reddy's Laboratories for ₹95 crore. Similarly, in the 2024 financial year, Corona acquired the muscle relaxant brand Myoril from Sanofi for ₹234 crore. Since taking over Myoril, the company has successfully increased its annual sales from ₹38 crore to ₹100 crore. The company has also acquired several other brands from major players, including Noklot from Bayer India, Vitneurin from GSK, and Obimet from Abbott India.
Why the 'Tail Brand' Strategy Matters
For many large pharmaceutical companies, certain older products become non-core as their focus shifts to newer therapeutic areas or larger global brands. These products often have strong legacy recognition among doctors and patients but suffer from a lack of active promotion.
By acquiring these brands, Corona Remedies skips the high costs, time, and risks associated with discovering and launching new drugs. Instead, it invests in re-engaging doctors, improving supply chains, and widening distribution to boost sales for brands that are already known in the market. This creates a faster path to scale compared to organic growth strategies.
Financial Performance
This focused approach has led to significant growth for the company. In the 2026 financial year, Corona Remedies reported revenue of ₹1,403.2 crore, which is a 17.3 percent increase over the previous year. This performance is notably higher than the 8.8 percent growth rate of the overall Indian Pharmaceutical Market. The company also reported a net profit of ₹199 crore, with operating profit margins expanding by 80 basis points compared to the previous year.
The Risks and Challenges
While the strategy of acquiring brands has proven successful so far, it comes with specific risks that investors should understand. One primary challenge is the risk of integration. Successfully maintaining or growing a brand requires effective sales force management and the ability to keep strong relationships with the doctors who prescribe these medicines. If the sales team is not able to align with the new brand or if there is a turnover of key personnel, the sales of these acquired brands could suffer.
Furthermore, many of these legacy brands are often essential medicines, which may be subject to government price controls. Changes in government regulations regarding drug pricing can impact the profitability of these products. There is also the constant risk of competition, as other companies may try to enter the same segment or offer generic alternatives at lower price points.
What Investors Should Track
Investors may monitor the company’s ability to successfully integrate new acquisitions into its existing sales network. The key monitorable will be whether the company can maintain or expand profit margins as it continues to take on more brands. Additionally, tracking the company’s ability to manage its debt and capital allocation—especially if it continues to acquire more assets—will be important. Future quarterly updates on how the new portfolio performs, particularly regarding volume growth versus price hikes, will also provide insight into the sustainability of this business model.